ALC-0315

Item number Size Datasheet Manual SDS Delivery time Quantity Price
Cay34337-25 25 mg -

5 - 10 business days*

290.00€
Cay34337-50 50 mg -

5 - 10 business days*

492.00€
Cay34337-100 100 mg -

5 - 10 business days*

695.00€
Cay34337-250 250 mg -

5 - 10 business days*

1,319.00€
Cay34337-1 1 g -

5 - 10 business days*

2,221.00€
 
ALC-0315 is an ionizable cationic lipid (pKa 6.09) that has been used in the generation of lipid... more
Product information "ALC-0315"
ALC-0315 is an ionizable cationic lipid (pKa 6.09) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA, siRNA, and plasmid DNA in vitro and in vivo. LNPs containing ALC-0315 and encapsulating siRNA targeting Factor VII mRNA decrease Factor VII mRNA levels in hepatocytes in mice. Administration of severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA in ALC-0315-containing LNPs induces the production of IgG that binds to the SARS-CoV-2 receptor-binding domain (RBD) in rhesus macaques, with a boost in antigen-specific IgG geometric mean titers (GMT) seven and 14 days after a second dose. LNPs containing ALC-0315 and encapsulating ovalbumin mRNA reduce tumor volume in an ovalbumin-expressing B16/F10 murine melanoma model. Formulations containing ALC-0315 have been used in the development of LNPs for the delivery of mRNA-based vaccines.. ALC-0315 is an ionizable cationic lipid (pKa 6.09) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA, siRNA, and plasmid DNA in vitro and in vivo. LNPs containing ALC-0315 and encapsulating siRNA targeting Factor VII mRNA decrease Factor VII mRNA levels in hepatocytes in mice. Administration of severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA in ALC-0315-containing LNPs induces the production of IgG that binds to the SARS-CoV-2 receptor-binding domain (RBD) in rhesus macaques, with a boost in antigen-specific IgG geometric mean titers (GMT) seven and 14 days after a second dose. LNPs containing ALC-0315 and encapsulating ovalbumin mRNA reduce tumor volume in an ovalbumin-expressing B16/F10 murine melanoma model. Formulations containing ALC-0315 have been used in the development of LNPs for the delivery of mRNA-based vaccines.. SMILES: OCCCCN(CCCCCCOC(C(CCCCCC)CCCCCCCC)=O)CCCCCCOC(C(CCCCCC)CCCCCCCC)=O. InChi Code: InChI=1S/C48H95NO5/c1-5-9-13-17-19-27-37-45(35-25-15-11-7-3)47(51)53-43-33-23-21-29-39-49(41-31-32-42-50)40-30-22-24-34-44-54-48(52)46(36-26-16-12-8-4)38-28-20-18-14-10-6-2/h45-46,50H,5-44H2,1-4H3. InChi Key: QGWBEETXHOVFQS-UHFFFAOYSA-N
Keywords: 2-hexyl-decanoic acid, 1,1'-[[(4-hydroxybutyl)imino]di-6,1-hexanediyl] ester
Supplier: Cayman Chemical
Supplier-Nr: 34337

Properties

Application: Ionizable amino lipid, lipid nanoparticle formation
MW: 766.3 D
Formula: C48H95NO5
Purity: >98%
Format: Solution

Database Information

CAS : 2036272-55-4| Matching products

Handling & Safety

Storage: -20°C
Shipping: -20°C (International: -20°C)
Signal Word: Danger
GHS Hazard Pictograms:
H Phrases: H225, H315, H319
P Phrases: P210, P233, P240, P241, P242, P243, P264, P280, P321, P302+P352, P303+P361+P353, P305+P351+P338, P332+P313, P337+P313, P362+P364, P370+P378, P403+P235, P501
Caution
Our products are for laboratory research use only: Not for administration to humans!
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "ALC-0315"
Write a review
or to review a product.
Viewed